High-risk human papillomavirus DNA test and p16INK4a in the triage of LSIL: A prospective diagnostic study

Gynecologic Oncology

Volumn 121, Issue 1, 2011, Pages 49-53

  Tsoumpou, I ^a   Valasoulis, G ^b   Founta, C ^b   Kyrgiou, M ^c   Nasioutziki, M ^d   Daponte, A ^e   Koliopoulos, G ^b   Malamou Mitsi, V ^b   Karakitsos, P ^f   Paraskevaidis, E ^b  

^a MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

^d ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^e UNIVERSITY HOSPITAL OF LARISSA   (Greece)

^f UNIVERSITY OF ATHENS   (Greece)

Author keywords

CIN; High risk human papillomavirus; LSIL; p16INK4a; PCR

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; VIRUS DNA;

ADULT; ARTICLE; COLPOSCOPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LOW GRADE SQUAMOUS INTRAEPITHELIAL LESION; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX BIOPSY; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; VIRUS DETECTION; WART VIRUS;

ADOLESCENT; ADULT; BIOPSY; CERVICAL INTRAEPITHELIAL NEOPLASIA; COLPOSCOPY; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA, VIRAL; FEMALE; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PROSPECTIVE STUDIES; RISK FACTORS; SENSITIVITY AND SPECIFICITY; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 79952818082     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2010.12.002     Document Type: Article

References (21)

1. Cervical screening programme, England: 2008-9. The health and social information centre; 2009.
2. Walker EM, Dodgson J, Duncan ID. Does mild atypia on a cervical smear warrant further investigation? Lancet 1986;ii:772-3.
3. Kyrgiou M, Koliopoulos G, Martin-Hirsch P, Kehoe S, Flannelly G, Mitrou S, et al. Management of minor cervical cytological abnormalities: a systematic review of the literature. Cancer Treat Rev 2007;33:514-20. (Pubitemid 47355339)
4. Cox JT, Schiffman M, Solomon D. Prospective follow-up suggests similar risk of subsequent cervical intraepithelial neoplasia grade 2 or 3 among women with cervical intraepithelial neoplasia grade 1 or negative colposcopy and directed biopsy. Am J Obstet Gynecol 2003;188:1406-12. (Pubitemid 36741266)
5. Kyrgiou M, Koliopoulos G, Martin-Hirsch P, Arbyn M, Prendiville W, Paraskevaidis E. Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis. Lancet 2006;367:489-98. (Pubitemid 43208905)
6. Arbyn M, Kyrgiou M, Simoens C, Raifu AO, Koliopoulos G, Martin-Hirsch P, et al. Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis. BMJ 2008;337:a1284.
7. TOMBOLA Group. Cytological surveillance compared with immediate referral for colposcopy in management of women with low-grade cervical abnormalities: multicentre randomized controlled trial. BMJ 2009;339:b2546.
8. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-9. (Pubitemid 29406813)
9. Munoz N. Human papillomavirus and cancer: the epidemiological evidence. J Clin Virol 2000;19:1-5.
10. Arbyn M, Buntinx F, Van Ranst M, Paraskevaidis E, Martin-Hirsch P, Dillner J. Virologic versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia. J Natl Cancer Inst 2004;96:280-93. (Pubitemid 38256273)
11. Arbyn M, Paraskevaidis E, Martin-Hirsch P, Prendiville W, Dillner J. Clinical utility of HPV-DNA detection: triage of minor cervical lesions, follow-up of women treated for high-grade CIN: an update of pooled evidence. Gynecol Oncol 2005;99 (3 Suppl 1):S7-S11. (Pubitemid 41774340)
12. Wentzensen N, von Knebel Doeberitz M. Biomarkers in cervical cancer screening. Dis Markers 2007;23:315-30. (Pubitemid 47015791)
13. Tsoumpou I, Arbyn M, Kyrgiou M, Wentzensen N, Koliopoulos G, Martin-Hirsch P, et al. p16INK4a immunostaining in cytological and histological specimens from the uterine cervix: a systematic review and meta-analysis. Cancer Treat Rev 2009;35:210-20.
14. CLART® (Clinical Array Technology) Human papillomavirus 2 kit, Genomica, Spain; 2009.
15. Dunne EF, Unger ER, Sternberg M, McQuillan G, Swan DC, Patel SS, et al. Prevalence of HPV infection among females in the United States. JAMA 2007;297:813-9. (Pubitemid 46333946)
16. CINtec® p16INK4a Cytology Kit , MTM laboratories, Heidelberg, Germany; 2006.
17. Klaes R, Friedrich T, Spitkovsky D, Ridder R, Rudy W, Petry U, et al. Overexpression of p16INK4a as a specific marker for dysplastic and neoplastic epithelial cells of the cervix. Int J Cancer 2001;92:276-84. (Pubitemid 32225381)
18. Monsonego J, Pollini G, Evrard MJ, Sednaoui P, Monfort L, Quinzat D, et al. P16INK4a immunocytochemistry in liquid-based cytology samples in equivocal Pap smears. Acta Cytol 2007;51:755-66.
19. Denton KJ, Bergeron C, Klement P, Trunk MJ, Keller R, European CINtec Cytology Study Group. The sensitivity and specificity of p16 (INK4a) cytology vs. HPV testing for detecting high-grade cervical disease in the triage of ASC-US and LSIL pap cytology results. Am J Clin Pathol 2010;134:12-21.
20. INK4a immunostaining in the risk assessment of women with LSIL cytology: a prospective pragmatic study. Eur J Gyn Oncol.
21. Wentzensen N, Bergeron C, Cas F, Eschenbach D, Vinokurova S, Doeberitz M. Evaluation of a nuclear score for p16INK4a-stained cervical squamous cells in liquid-based cytology samples. Cancer 2005;105:461-7. (Pubitemid 43067004)